A nossa Palestrante convidada,
Dr Esther Pearl, é do National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) , London - UK. She
is the
Programme Manager for Experimental design and works to develop tools and resources to
help researchers design experiments. This includes the Experimental Design Assistant (EDA), an online tool to guide researchers through the design of animal experiments, and the ARRIVE guidelines, which encourage improved design and reporting of animal research. Esther completed a PhD in Biochemistry at the University of Otago, New
Zealand and worked with
Xenopus as a postdoctoral researcher in the field of developmental biology at the Clinical Research institute of Montreal, Canada, the National Xenopus Resource, USA and King’s College London, UK.
Segue abaixo os detalhes do evento:
There is growing concern in the community about the reliability of
biomedical research results. Experimental design flaws, inappropriate
analysis methods and incomplete reporting have all contributed to the
publishing of inconsistent results. The NC3Rs has developed resources
to assist researchers in designing more robust experiments, selecting
the appropriate analysis method and reporting the experiment
thoroughly. One such resource is the Experimental Design Assistant
(EDA; https://eda.nc3rs.org.uk ).
The EDA is free online software with a supporting website to help
researchers design more robust in vivo experiments.
This talk will cover
key strategies to improve experimental design and highlight how the
EDA can help researchers implement these. For example, the EDA can
analyse your experimental design and suggest changes or highlight the
implications of your specific experimental design choices, enabling
you to make informed choices. Optimised experimental plans can then
be communicated by exporting a PDF summarizing key experimental
design information from the EDA or sharing your experimental plan via
a URL. This can make clearly communicating experimental plans with
colleagues, funders and ethical review bodies easier, enhancing
opportunities for collaboration, feedback and transparent reporting
of your in vivo experiments.
